<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02266030</url>
  </required_header>
  <id_info>
    <org_study_id>B-1010/114-005</org_study_id>
    <nct_id>NCT02266030</nct_id>
  </id_info>
  <brief_title>Effect of Cilostazol on Coronary Artery Stenosis and Plaque Characteristics in Patients With T2DM</brief_title>
  <acronym>ESCAPE</acronym>
  <official_title>Effect of Cilostazol on Coronary Artery Stenosis and Plaque Characteristics in Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Bundang Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective interventional study to assess the effect of cilostazol compared with&#xD;
      aspirin in Korean T2DM patients with atherosclerosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type 2 diabetes has been increased exponentially, arousing serious economic, social and&#xD;
      health repercussions. Also, macrovascular complications of diabetes such as myocardial&#xD;
      infarct or stroke have been increased. Individuals with diabetes have a greater risk of&#xD;
      cardiovascular disease (CVD), approximately two to four times than that of those without&#xD;
      diabetes. Currently, the U.S. Food and Drug Administration requires demonstration that new&#xD;
      anti-hyperglycemic agents do not increase CV risk. The comprehensive and multifactorial&#xD;
      management in type 2 diabetes, which includes control of hypertension, dyslipidemia and&#xD;
      obesity, is known to significantly reduce the risk of CVD as shown in Steno-2 study. However,&#xD;
      most anti-diabetic agents currently used in clinical practice do not seem to provide enough&#xD;
      CV protection.&#xD;
&#xD;
      This is a prospective interventional study to assess the effect of cilostazol compared with&#xD;
      aspirin in Korean T2DM patients with atherosclerosis. T2DM patients who have coronary artery&#xD;
      stenosis by MDCT at least 3 months prior to this investigation will be enrolled.&#xD;
&#xD;
      Considering drop out due to adverse events or follow up loss, sufficient patients will be&#xD;
      enrolled. Their medical record will be reviewed and relevant clinical and laboratory findings&#xD;
      will be collected.&#xD;
&#xD;
      Cardiac computed tomography (CT) was introduced in the early 1990s. However, electron-beam CT&#xD;
      (EBCT) only provided information on simple coronary artery calcium score (CAC). Recently,&#xD;
      MDCT has been introduced, which can evaluate coronary arteries comprehensively. MDCT images&#xD;
      can provide measurements of CAC, the degree of stenosis, and the characteristics of plaque&#xD;
      including its potential vulnerability. These findings of MDCT have been reported to be in&#xD;
      good agreement with intravascular ultrasound.&#xD;
&#xD;
      All scans are analyzed independently by two experienced investigators using a 3D workstation,&#xD;
      who are blinded to the clinical information (Brilliance; Philips Medical Systems). After&#xD;
      independent evaluations are made, a consensus interpretation is arrived at regarding the&#xD;
      final MDCT diagnosis. Each lesion is identified using a multiplanar reconstruction technique&#xD;
      and maximum intensity projection of the short axis, in two-chamber and four-chamber views.&#xD;
      Image quality is evaluated on a per-segment basis and classified. Plaque characteristics on a&#xD;
      per-segment basis are analyzed according to the modified American Heart Association&#xD;
      classification.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Coronary artery stenosis</measure>
    <time_frame>one year</time_frame>
    <description>Severity of coronary artery stenosis (%)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plaque characteristics</measure>
    <time_frame>one year</time_frame>
    <description>Noncalified plaque</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plaque characteristics</measure>
    <time_frame>one year</time_frame>
    <description>Mixed plaque</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plaque characteristics</measure>
    <time_frame>one year</time_frame>
    <description>Calcified plaque</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multivessel involvement</measure>
    <time_frame>one year</time_frame>
    <description>Multivessel involvement in coronary arteries</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Main vessel involvement</measure>
    <time_frame>one year</time_frame>
    <description>Left main and/or proximal LAD stenosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coronary artery calcium (CAC) score</measure>
    <time_frame>one year</time_frame>
    <description>Agatston score for CAC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose homeostasis</measure>
    <time_frame>one year</time_frame>
    <description>Changes in HbA1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose homeostasis</measure>
    <time_frame>one year</time_frame>
    <description>Changes in fasting glucose concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid metabolism</measure>
    <time_frame>one year</time_frame>
    <description>Changes in TG concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid metabolism</measure>
    <time_frame>one year</time_frame>
    <description>Changes in HDL-concentration concentration</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Bleeding risk</measure>
    <time_frame>one year</time_frame>
    <description>Any type of bleeding</description>
  </other_outcome>
  <other_outcome>
    <measure>Headache</measure>
    <time_frame>one year</time_frame>
    <description>Any type of headache</description>
  </other_outcome>
  <other_outcome>
    <measure>Heart rate</measure>
    <time_frame>one year</time_frame>
    <description>Frequence of heart beat per min</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Cilostazol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cilostazol 100-200 mg qd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Asprin 100mg qd for active comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cilostazol</intervention_name>
    <description>Pletaal as an active drug</description>
    <arm_group_label>Cilostazol</arm_group_label>
    <other_name>Pletaal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Aspirin as an active comparator</description>
    <arm_group_label>Aspirin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 2 diabetes with HbA1c ≥ 6.0% at screening visit&#xD;
&#xD;
          -  Male or female between 30 and 80 years of age&#xD;
&#xD;
          -  Coronary artery stenosis: 25-75% without no evidence of acute coronary syndrome&#xD;
&#xD;
          -  No history of previous myocardial infarction&#xD;
&#xD;
          -  Estimated GFR ≥ 60 ml/min/1.73m²&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  SBP/DBP&gt; 160/110&#xD;
&#xD;
          -  Congestive heart failure&#xD;
&#xD;
          -  Allegy to radiocontrast dye&#xD;
&#xD;
          -  Allegy to aspirin or cilostazol&#xD;
&#xD;
          -  Acute bleeding&#xD;
&#xD;
          -  History of ulcer bleeding&#xD;
&#xD;
          -  GOT/GPT &gt; 100/100&#xD;
&#xD;
          -  Other antiplatlet medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Soo Lim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SNUBH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <state>Bundang-gu</state>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>October 11, 2014</study_first_submitted>
  <study_first_submitted_qc>October 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2014</study_first_posted>
  <last_update_submitted>October 5, 2017</last_update_submitted>
  <last_update_submitted_qc>October 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>Soo Lim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Coronary Stenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Cilostazol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

